Arthritis drug shows promise for rare, Life-Threatening skin conditions
NCT ID NCT06474078
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested the drug tofacitinib (XELJANZ) in 20 adults with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), rare and severe skin reactions often caused by medications. The main goal was to see how quickly the skin healed completely. Researchers also tracked deaths, hospital stay length, side effects, and eye complications. The study was small and had no placebo group, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tofacitinib (XELJANZ)
- What this could lead to
- If it works, this could point toward a faster skin-healing treatment for severe drug reactions like SJS/TEN.
- What could go wrong
- This was a very small pilot study with only 20 people and no comparison group, so results may not apply broadly. Tofacitinib can increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Aug 2022
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Willing to sign inform consent form 2. Subject has been diagnosed with Stevens-Johnson syndrome or toxic epidermal necrolysis by at least two dermatologists. 3. Male or female aged over 20 years old and under 90 years old. Exclusion Criteria: 1. Subject or legally authorized representative is not willing to provide informed consent. 2. Women who are pregnant or breastfeeding 3. Subject has an active, untreated, or serious infectious disease that is ineffective in treatment, such as sepsis. 4. Subject suffers from severe life-threatening cardiac arrhythmia, such as ventricular tachycardia, have had myocardial infarction (myocardial infarction), severe hypertension that has not responded to treatment within the past week, or other cardiologist diagnosed severe cardiovascular disease 5. Subject has active viral hepatitis 6. Subject has active tuberculosis 7. Subject received live vaccination during the illness
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stevens-Johnson syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
- Could a simple ingredient boost dry eye drops?
- Planned study on severe skin reactions withdrawn before starting
- Can a white blood cell booster heal a rare skin emergency?
- Contact lens coating replenisher tested for rare eye conditions
- Small study tests drug for rare, Life-Threatening skin condition